Aquestive Therapeutics (AQST) Net Margin (2017 - 2026)

Aquestive Therapeutics' Net Margin history runs 10 years deep, the most recent figure standing at 55.77% for Q1 2026.

• On a quarterly basis, Net Margin rose 20719.0% year-over-year to 55.77% in Q1 2026; TTM through Mar 2026 was 1034.08%, a 93406.0% decrease from a year earlier, with the FY2025 full-year figure at 8932.2%, down 885552.0% from the prior year.
• Net Margin retreated to 55.77% in Q1 2026 per AQST's latest filing, from 104.14% in the prior quarter.
• Across five years, Net Margin topped out at 104.14% in Q4 2025 and bottomed at 262.96% in Q1 2025.
• The 5-year median for Net Margin is 106.43% (2024), against an average of 82.61%.
• Across the five-year window, Net Margin soared 41458 bps in 2022 and sank 17889 bps in 2024, its largest moves.
• Year by year, Net Margin stood at 115.63% in 2022, then jumped by 47 bps to 61.42% in 2023, then tumbled by 134 bps to 143.72% in 2024, then soared by 172 bps to 104.14% in 2025, then slumped by 154 bps to 55.77% in 2026.
• Per Business Quant, the three latest AQST Net Margin figures stand at 55.77% (Q1 2026), 104.14% (Q4 2025), and 120.61% (Q3 2025).